|
|
Article: LUNESTA Perimenopause-Menopause Study Shows Improvement for Women Suffering from Insomnia.
- Article from:
- Business Wire
- Article date:
- July 18, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MARLBOROUGH, Mass. -- Sepracor Inc. (Nasdaq: SEPR) today announced preliminary results from its Phase IIIB/IV, 410-patient, four-week, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of LUNESTA(TM) brand eszopiclone for the treatment of insomnia in perimenopausal and menopausal women suffering from insomnia. The results of this study will be presented at The North American Menopause Society's annual meeting in San Diego on Sept. 30, 2005.
In this study, nightly use of LUNESTA 3 mg resulted in statistically significant improvement (p
Compared to baseline and averaged over the double-blind period, women treated with LUNESTA ...